Evaxion Biotech A/S Annual General Meeting approved carrying forward 2025 financial year loss, re-elected four board members, elected one new director, and authorized expanded board powers for warrants up to DKK 11,900,000 and convertible loan notes up to DKK 73,500,000.
Key takeaways
Loss for financial year 2025 transferred to next financial year.
Marianne Søgaard, Lars Holtug, Lars Aage Staal Wegner, and Roberto Prego Pineda re-elected to board of directors.
Jens Bitsch-Nørhave elected as new board member.
Board authorized until April 15, 2029 to issue warrants for shares up to nominal DKK 11,900,000 without pre-emptive rights.
Board authorized until April 15, 2031 to issue convertible loan notes for shares up to nominal DKK 73,500,000 without pre-emptive rights.
Articles of Association amended effective April 16, 2026 as Exhibit 3.1.